Search results
Earnings call: Fulcrum Therapeutics partners with Sanofi on FSHD drug By Investing.com
Investing.com· 2 weeks agoFulcrum (LON:FMETF) Therapeutics (ticker: NASDAQ:FULC) has entered into a significant collaboration...
Fulcrum Therapeutics stock target lifted, maintains buy on Sanofi deal By Investing.com
Investing.com· 2 weeks agoOn Monday, Stifel, a financial services firm, raised its price target on shares of Fulcrum...
Moderna and Pfizer In Talks With U.S. To Make a Bird Flu Vaccine
Barrons.com· 4 days agoLast year, the company began early-stage tests of a number of avian flu vaccines that target...
Massachusetts Financial Services Co. MA Boosts Holdings in Sanofi (NASDAQ:SNY)
ETF DAILY NEWS· 6 days agoMassachusetts Financial Services Co. MA raised its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 8.6% in the fourth quarter, according to the company in its most ...
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the...
Morningstar· 2 weeks agoUnder the collaboration and license agreement, Sanofi obtains exclusive commercialization rights for losmapimod outside of the U.S.
Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi
Yucaipa News Mirror· 2 days agoInhibrx, Inc. (Nasdaq: INBX) ("Inhibrx," or the "Company") announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the sale to Sanofi
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
FX Empire via Yahoo Finance· 2 weeks agoThe past five days have been a rollercoaster for Novavax investors, as the share price of the...
PNC Financial Services Group Inc. Sells 93,285 Shares of Sanofi (NASDAQ:SNY)
ETF DAILY NEWS· 1 day agoPNC Financial Services Group Inc. lowered its position in Sanofi (NASDAQ:SNY – Free Report) by 48.1% during the fourth quarter, Holdings Channel reports. The institutional ...
Dupixent set for FDA review in adolescent chronic inflammatory sinus disease
Pharmaceutical Technology via Yahoo Finance· 2 weeks agoRegeneron and Sanofi could soon be adding another indication to its blockbuster immunology drug...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with...
Benzinga· 2 weeks agoRegeneron Pharmaceuticals, Inc. REGN and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority ...